Curis Inc (CRIS) SEC filings

CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30

$0.45−0.13 (-22.18%)

Close on Nov 13, 2026Market cap $930.08KP/E –Yield –

SEC filings

40 of Curis's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 13, 2026	SEC EDGAR
Current report	8-K	Nov 12, 2026	Nov 13, 2026	SEC EDGAR
Current report	8-K	Nov 2, 2026	Nov 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Nov 18, 2026	Nov 2, 2026	SEC EDGAR
Current report	8-K	Oct 16, 2026	Oct 19, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Jul 24, 2026	Jul 30, 2026	SEC EDGAR
Current report	8-K	Jul 2, 2026	Jul 2, 2026	SEC EDGAR
Current report	8-K	Jun 25, 2026	Jul 1, 2026	SEC EDGAR
Current report	8-K	Jun 25, 2026	Jun 25, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 25, 2026	Jun 5, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 22, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	Apr 27, 2026	May 1, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 19, 2026	Apr 21, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 24, 2026	SEC EDGAR
Current report	8-K	Mar 19, 2026	Mar 19, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Proxy statement	DEF 14A	Mar 17, 2026	Feb 19, 2026	SEC EDGAR
Current report	8-K	Feb 3, 2026	Feb 9, 2026	SEC EDGAR
Current report	8-K	Jan 7, 2026	Jan 8, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Oct 20, 2025	Oct 24, 2025	SEC EDGAR
Current report	8-K	Aug 21, 2025	Aug 22, 2025	SEC EDGAR
Current report	8-K	Aug 8, 2025	Aug 8, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 5, 2025	SEC EDGAR
Current report	8-K	Aug 5, 2025	Aug 5, 2025	SEC EDGAR
Current report	8-K	Jul 1, 2025	Jul 2, 2025	SEC EDGAR
Current report	8-K	May 20, 2025	May 22, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 6, 2025	SEC EDGAR
Current report	8-K	May 6, 2025	May 6, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 20, 2025	Apr 10, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 31, 2025	SEC EDGAR
Current report	8-K	Mar 31, 2025	Mar 31, 2025	SEC EDGAR
Current report	8-K	Mar 28, 2025	Mar 28, 2025	SEC EDGAR
Current report	8-K	Feb 21, 2025	Feb 27, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 14, 2024	SEC EDGAR
Current report	8-K	Nov 14, 2024	Nov 14, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Curis's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Jul 6, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CRIS.

Compare: CRIS vs MOLN · CRIS vs RLAY · CRIS vs TCRX · CRIS vs IMNM · CRIS vs ELOX

Revenue growth-13.4% · median -38.4%

Operating margin-112.1% · median -3094.6%

Net margin-228.1% · median -2837.0%

Company	Revenue	Growth
RLAY	$10.35M	+23.9%
CRIS	$9.44M	-13.4%
TCRX	$5.19M	-38.4%
IMNM	$4.02M	-63.3%
MOLN	–	–
ELOX	–	–

Company

Next earnings (est.): Mar 18, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 24
Held by institutions: 32.1%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1108205

Advertisement
300 × 250

See a number that looks wrong?